According to the latest report by IMARC Group "Erythropoietin Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027", The global erythropoietin drugs market size reached US$ 9.8 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 13.8 Billion by 2027, exhibiting a growth rate (CAGR) of 5.75% during 2022-2027.

Erythropoietin (EPO) or hematopoietin is a hormone generated by kidneys to stimulate the production of red blood cells (RBCs) in the body. Its deficiency can lead to low levels of hemoglobin and several medical conditions. Consequently, there is increasing demand for EPO drugs, also known as EPO stimulating agents (ESAs), artificially produced through recombinant deoxyribonucleic acid (DNA) technology. They are generally administered intramuscularly and released into the bloodstream to trigger RBC production. They are also prescribed to patients undergoing chemotherapy, antiviral drug therapy, chronic renal failure, and at a high risk of perioperative blood loss from surgery. As a result, erythropoietin drugs are available in varying dosages and delivery modes across home care, specialty clinics, and hospitals.

Request for a free sample copy of this report: https://www.imarcgroup.com/erythropoietin-drugs-market/requestsample

Market Trends:

The market is primarily driven by the increasing prevalence of chronic ailments such as kidney problems, cancer, neurological disorders, and acquired immunodeficiency syndrome (AIDS). In addition, the increasing use of erythropoietin for treating anemia caused due to several conditions, such as chemotherapy, end-stage renal disease (ESRD), radiotherapy, and antiretroviral treatments (ART), are contributing to the market growth. Moreover, various governments are taking initiatives to incentivize research on chronic diseases and encouraging individuals through grants, tax credits, drug exclusivity, and fee waivers to develop novel erythropoietin drug products, representing another major growth-inducing factor. Besides this, the rapid commercialization of cost-effective biosimilars, which are easy to switch, require less approval time, and are commonly used in chemotherapy cycles, is accelerating the product adoption rate. Furthermore, the growing incidence of end-stage renal diseases (dialysis), the recent repurposing of EPO drugs for treating diabetes mellitus (DM), and the rising strategic collaborations among drug manufacturers due to high return on investment (ROI) are creating a favorable global market outlook.

Breakup by Drug Class:

  • Biologics
  • Biosimilars

Breakup by Product Type:

  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • Others

Breakup by Application:

  • Hematology
  • Kidney Disorder
  • Cancer
  • Others

Breakup by End User:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Market Breakup by Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

Competitive Landscape with Key Player:

  • Amgen Inc.
  • Biocon Limited
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • LG Chem Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.

Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/erythropoietin-drugs-market

Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Contact US

IMARC Group

Email: sales@imarcgroup.com

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Address: 134 N 4th St. Brooklyn, NY 11249, USA 

Follow us on Twitter: @imarcglobal